$MDLN Investigation Notification: Suffer Losses on Your Medline Investment? BFA Law Reminds Investors of the Ongoing Securities Fraud Investigation

Bleichmar Fonti & Auld LLP (BFA Law) announced an investigation into Medline (NASDAQ: MDLN) for potential securities fraud related to statements about manufacturing and product quality. The release cites an FDA warning letter over Current Good Manufacturing Practice violations, which drove a roughly 7% stock drop on June 2, 2026, followed by a ~13% drop on August 5, 2026 after Medline said remediation resulted in earnings loss on its Q2 call.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.